These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9250565)

  • 1. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations.
    McCune JS; Liles D; Lindley C
    Pharmacotherapy; 1997; 17(4):822-6. PubMed ID: 9250565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations--a comment.
    Petitt RM
    Pharmacotherapy; 1998; 18(3):659; discussion 660-1. PubMed ID: 9620121
    [No Abstract]   [Full Text] [Related]  

  • 3. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
    Trapp OM; Beykirch MK; Petrides PE
    Blood Cells Mol Dis; 1998 Mar; 24(1):9-13. PubMed ID: 9516377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT
    Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytosis--report of a case.
    Thomas M; Pavithran K; Salil ; Somarajan A
    J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
    Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypersensitivity pneumonitis associated with anagrelide.
    Raghavan M; Mazer MA; Brink DJ
    Ann Pharmacother; 2003 Sep; 37(9):1228-31. PubMed ID: 12921504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anagrelide in primary thrombocythemia].
    Knutsen H; Hysing J
    Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
    Voskaridou E; Terpos E; Komninaka V; Eftyhiadis E; Mantzourani M; Loukopoulos D
    Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of anagrelide in the treatment of thrombocytosis.
    Brooks WG; Stanley DD; Goode JV
    Ann Pharmacother; 1999 Oct; 33(10):1116-8, 1121. PubMed ID: 10534225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.